Decade-long preclinical studies of A2AR antagonists in PD models led to clinical trials of the A2AR antagonist istradefylline, which confirmed its clinically significant motor benefit in advanced PD patients and resulted in the approval of istradefylline for the treatment of PD patients in Japan and the US. Here, ADORA2A is linked to Parkinson disease.